363 related articles for article (PubMed ID: 31981984)
1. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
2. Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells.
Tseng WL; Chou SJ; Chiang HC; Wang ML; Chien CS; Chen KH; Leu HB; Wang CY; Chang YL; Liu YY; Jong YJ; Lin SZ; Chiou SH; Lin SJ; Yu WC
Cell Transplant; 2017 Mar; 26(3):513-527. PubMed ID: 27938475
[TBL] [Abstract][Full Text] [Related]
3. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.
Choi JB; Seol DW; Do HS; Yang HY; Kim TM; Byun YG; Park JM; Choi J; Hong SP; Chung WS; Suh JM; Koh GY; Lee BH; Wee G; Han YM
Mol Ther; 2023 Apr; 31(4):1002-1016. PubMed ID: 36755495
[TBL] [Abstract][Full Text] [Related]
4. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
Choi JB; Seo D; Do HS; Han YM
Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
[TBL] [Abstract][Full Text] [Related]
5. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation.
Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551
[TBL] [Abstract][Full Text] [Related]
6. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
7. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cellular phenotypes in neurons derived from induced pluripotent stem cells of male patients with Fabry disease.
Miyajima T; Saito R; Yanagisawa H; Igarashi M; Wu C; Iwamoto T; Eto Y
J Inherit Metab Dis; 2023 Jan; 46(1):143-152. PubMed ID: 36220782
[TBL] [Abstract][Full Text] [Related]
9. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
[TBL] [Abstract][Full Text] [Related]
10. Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.
Park JL; Shu L; Shayman JA
Am J Physiol Heart Circ Physiol; 2009 Apr; 296(4):H1133-40. PubMed ID: 19202000
[TBL] [Abstract][Full Text] [Related]
11. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
[TBL] [Abstract][Full Text] [Related]
12. Generation of
Song HY; Chien CS; Yarmishyn AA; Chou SJ; Yang YP; Wang ML; Wang CY; Leu HB; Yu WC; Chang YL; Chiou SH
Cells; 2019 Apr; 8(4):. PubMed ID: 30965672
[TBL] [Abstract][Full Text] [Related]
13. Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model.
Park ES; Choi JO; Park JW; Lee MH; Park HY; Jung SC
Int J Mol Med; 2009 Sep; 24(3):401-7. PubMed ID: 19639234
[TBL] [Abstract][Full Text] [Related]
14. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach.
Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103
[TBL] [Abstract][Full Text] [Related]
15. Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation.
Pollmann S; Scharnetzki D; Manikowski D; Lenders M; Brand E
Front Immunol; 2021; 12():789142. PubMed ID: 34917096
[TBL] [Abstract][Full Text] [Related]
16. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease.
Song HY; Chiang HC; Tseng WL; Wu P; Chien CS; Leu HB; Yang YP; Wang ML; Jong YJ; Chen CH; Yu WC; Chiou SH
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983599
[TBL] [Abstract][Full Text] [Related]
17. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.
Lee MH; Choi EN; Jeon YJ; Jung SC
Int J Mol Med; 2012 Dec; 30(6):1275-80. PubMed ID: 23007467
[TBL] [Abstract][Full Text] [Related]
18. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation.
Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 77():103404. PubMed ID: 38552356
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model.
Cui S; Shin YJ; Fang X; Lee H; Eum SH; Ko EJ; Lim SW; Shin E; Lee KI; Lee JY; Lee CB; Bae SK; Yang CW; Chung BH
Transl Res; 2023 Aug; 258():35-46. PubMed ID: 36805562
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
